Evidence map›Paper›PMID 41000875›Full record

ArticlebioRxiv : the preprint server for biology2025

Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistance.

Haiyin Li, Yeqing Chen, Jessica Kaster, Maggie Dunne, Min Xiao, Ling Li, Monzy Thomas, Nazifa Promi, Dylan Fingerman, Gregory Schuyler Brown and 23 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Haiyin LiThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0001-6205-7588
Yeqing ChenThe Wistar Institute, Philadelphia, PA, USA.
Jessica KasterThe Wistar Institute, Philadelphia, PA, USA.
Maggie DunneThe Wistar Institute, Philadelphia, PA, USA.
Min XiaoThe Wistar Institute, Philadelphia, PA, USA.
Ling LiThe Wistar Institute, Philadelphia, PA, USA.
Monzy ThomasThe Wistar Institute, Philadelphia, PA, USA.
Nazifa PromiThe Wistar Institute, Philadelphia, PA, USA.
Dylan FingermanThe Wistar Institute, Philadelphia, PA, USA.
Gregory Schuyler BrownThe Wistar Institute, Philadelphia, PA, USA.
Qiuxian ZhengThe Wistar Institute, Philadelphia, PA, USA.
Xingyue ZhuThe Wistar Institute, Philadelphia, PA, USA.
McKenna RealeThe Wistar Institute, Philadelphia, PA, USA.
Andrew PattersonThe Wistar Institute, Philadelphia, PA, USA.
Le GaoDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.
Xuxiang ZhangDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.
Siqi JiangDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.
Tianxing HuDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.
Hanzhang FangDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.
Jianlan RenDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.
Cong QiDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.
Luyang WangThe Wistar Institute, Philadelphia, PA, USA.
Haiwei MouThe Wistar Institute, Philadelphia, PA, USA.
Gatha ThackerThe Wistar Institute, Philadelphia, PA, USA.
Eric Ramirez SalazarThe Wistar Institute, Philadelphia, PA, USA.
Jessie VillanuevaThe Wistar Institute, Philadelphia, PA, USA.
Arjun RajDepartment of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Dave Sb HoonSt John's Cancer Institute, Santa Monica, CA, USA.
Tian BinThe Wistar Institute, Philadelphia, PA, USA.
Jozef MadzoThe Wistar Institute, Philadelphia, PA, USA.
Zhi WeiDepartment of Computer Science, New Jersey Institute of Technology, Newark, NJ, USA.
Noam AuslanderThe Wistar Institute, Philadelphia, PA, USA.
Meenhard HerlynThe Wistar Institute, Philadelphia, PA, USA.ORCID 0000-0003-0839-0739

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2008 to 2023
$37.1M
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Jessie Villanueva · 2017 to 2026
$13.9M
Targeting exosomal PDL1 to improve immunotherapyP50CA261608 · NCI · WISTAR INSTITUTE · PI VILLANUEVA, JESSIE · 2021 to 2025
$11.3M
Targeting Aldehyde Dehydrogenase for Cancer PreventionR01CA241148 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI ROBERTSON, GAVIN P., SCHELL, TODD D · 2020 to 2024
$3.1M
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in MelanomaR01CA238237 · NCI · UNIVERSITY OF PENNSYLVANIA · PI HERLYN, MEENHARD F, RAJ, ARJUN · 2020 to 2024
$2.9M
Regulation of gene expression by alternative polyadenylationR35GM153277 · NIGMS · WISTAR INSTITUTE · PI BIN TIAN · 2024 to 2026
$2.0M
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALINGR01CA240362 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI POULIKAKOS, POULIKOS I · 2020 to 2024
$2.0M
NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA261608NCI NIH HHS R01 CA238237NCI NIH HHS R01 CA240362NCI NIH HHS R01 CA241148NCI NIH HHS U54 CA224070NIGMS NIH HHS R35 GM153277
6 · The paper itself

Abstract

Most advanced melanomas initially respond to targeted therapy but eventually relapse. Rather than acquiring new mutations, resistance is driven by drug-tolerant persister cells that enter a reversible drug-refractory state. We developed MeRLin, a high-resolution lineage tracing platform integrating cellular barcoding, single-cell transcriptomics, RNA fluorescence in situ hybridization (FISH), and computational analyses to track clonal and transcriptional dynamics in patient-derived melanoma models during prolonged therapy. Clonal dynamics revealed that persister subpopulations first responded to treatment but persisted and expanded during minimal residual disease, ultimately leading to tumor recurrence. Pre-treatment melanoma populations diversified into four conserved persister states characterized by stress-like, lipid metabolism, PI3K signaling, and extracellular matrix remodeling programs associated with adaptive resistance. Spatial transcriptomics showed the organization of these adaptive programs and a complex signaling network of autocrine and paracrine interactions among persister subpopulations. Barcoded RNA-FISH enabled spatial mapping of clonal identity and gene expression, revealing

Identifiers

PMID41000875
PMCPMC12458950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.